Nluc Reporter Cell Line - calu-6

The Calu-6 cell line is a human non-small cell lung cancer (NSCLC) cell line derived from the pleural effusion of a 61-year-old male patient. Established in 1975, this cell line has been an important model for lung cancer research. Calu-6 cells exhibit a unique epithelial morphology and are widely used to study the biological characteristics of lung cancer, including metastatic mechanisms, drug resistance, and the tumor microenvironment. Their ability to form tumors in xenograft models is particularly notable, making them invaluable for in vivo studies of tumor growth and response to therapeutic agents.

The Nluc reporter gene cell line - Calu-6 has been genetically engineered to express NanoLuc luciferase (Nluc), a novel bioluminescent reporter enzyme that offers higher brightness and stability compared to traditional luciferases. This modification enables highly sensitive and quantitative detection of cellular responses in real-time assays. Applications include high-throughput drug screening, where the reporter system monitors the efficacy or toxicity of compounds by measuring changes in luminescence signals related to cell viability, apoptosis, or pathway activation (e.g., NF-κB signaling pathway). Furthermore, it facilitates gene expression studies through promoter-reporter gene constructs, allowing researchers to track changes in transcriptional activity induced by stimuli such as cytokines or hypoxia. The Nluc-Calu-6 cell line is particularly well-suited for in vivo imaging in xenograft models, where non-invasive bioluminescent tracking can provide longitudinal data on tumor growth and treatment response.